{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-041917","form_type":"8-K","ticker":null,"cik":"0001822711","company_name":"PARDES BIOSCIENCES, INC.","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.458213+00:00","generated_at":"2026-06-11T01:25:00.821698+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Pardes Biosciences acquired by Foresite Capital affiliate for $2.13/share plus CVR; delisted from Nasdaq","bullets":["Tender offer expired Aug 30, 2023; 37,836,066 shares (~60.9% of outstanding) validly tendered.","Shareholders received $2.13 cash per share plus a non-tradeable CVR linked to future monetization of COVID-19 antiviral assets.","After the tender close, Merger Sub merged with Pardes; company became wholly owned subsidiary of MediPacific (Foresite Capital).","All shares ceased trading on Nasdaq prior to Aug 31, 2023; deregistration intended.","Board of directors resigned; new directors from Merger Sub include James B. Tananbaum and Dennis D. Ryan."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-041917","json":"https://secwatch.observer/filing/0001140361-23-041917.json","markdown":"https://secwatch.observer/filing/0001140361-23-041917.md","text":"https://secwatch.observer/filing/0001140361-23-041917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/brhc20058194_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:25:00.821698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d571492ac","claim":"James B. Tananbaum was appointed as Director, President and Chief Executive Officer at PARDES BIOSCIENCES, INC..","evidence_excerpt":"The directors and officers of Merger Sub immediately prior to the Effective Time were James B. Tananbaum, Director, President and Chief Executive Officer, and Dennis D. Ryan, director, Chief Financial Officer and Secretary.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director, President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"3318105582","claim":"Deborah M. Autor resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"42ff233658","claim":"Mark Auerbach resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"68ef606482","claim":"Dennis D. Ryan was appointed as Director, Chief Financial Officer and Secretary at PARDES BIOSCIENCES, INC..","evidence_excerpt":"The directors and officers of Merger Sub immediately prior to the Effective Time were James B. Tananbaum, Director, President and Chief Executive Officer, and Dennis D. Ryan, director, Chief Financial Officer and Secretary.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director, Chief Financial Officer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"7cf781f927","claim":"Michael Varney resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8bebd12452","claim":"John C. Pottage Jr. resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a00ceb3bdd","claim":"Laurie Smaldone Alsup resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a7a30ba93b","claim":"Laura J. Hamill resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"dfc9be2a3a","claim":"Thomas G. Wiggans resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e579ee008f","claim":"J. Jay Lobell resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e5af752a47","claim":"Uri A. Lopatin resigned as Director at PARDES BIOSCIENCES, INC..","evidence_excerpt":"each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0038b1af8704266dbdf952520d8cafd2db35ddb8","claim":"PARDES BIOSCIENCES, INC.: The bylaws were amended and restated in their entirety (effective 2023-08-31).","evidence_excerpt":"on August 31, 2023, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, copies of which are attached to this Current Report on Form 8-K as Exhibit 3.1 and Exhibit 3.2, respectively.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-08-31"}],"fact_type":"governance_change"},{"claim_id":"aaaf4cc06ecbcff9b1f202087826c4fd7d39af11","claim":"PARDES BIOSCIENCES, INC.: The certificate of incorporation was amended and restated in its entirety (effective 2023-08-31).","evidence_excerpt":"on August 31, 2023, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, copies of which are attached to this Current Report on Form 8-K as Exhibit 3.1 and Exhibit 3.2, respectively.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-31"}],"fact_type":"governance_change"},{"claim_id":"e22377267475b6ea541c7949106042405424312f","claim":"PARDES BIOSCIENCES, INC. underwent a change of control involving MediPacific, Inc., MediPacific Sub, Inc. for the Offer Price (i) $2.13 per share of Common Stock (the \"Cash Amount\") and (ii) one contingent value right (a \"CVR\") (closed 2023-08-31).","evidence_excerpt":"Merger Sub commenced a tender offer to purchase all of the C ompany’s outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), in exchange for (i) $2.13 per share of Common Stock (the “Cash Amount”) and (ii) one contingent value right (a “CVR”) associated with any future monetization of the Company’s antiviral drug development","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"MediPacific, Inc., MediPacific Sub, Inc."},{"label":"Consideration","value":"the Offer Price (i) $2.13 per share of Common Stock (the \"Cash Amount\") and (ii) one contingent value right (a \"CVR\")"},{"label":"Closing","value":"2023-08-31"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}